[1]王兴纯,曲伸.GLP-1及其受体激动剂与炎性反应及氧化应激[J].国际内分泌代谢杂志,2014,(04):263-266.[doi:10.3760/cma.j.issn.1673-4157.2014.04.014]
　Wang Xingchun,Qu Shen..Association of GLP-1 and its receptor agonist with inflammation and oxidative stress[J].International Journal of Endocrinology and Metabolism,2014,(04):263-266.[doi:10.3760/cma.j.issn.1673-4157.2014.04.014]
点击复制

GLP-1及其受体激动剂与炎性反应及氧化应激()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
期数:
2014年04期
页码:
263-266
栏目:
综述
出版日期:
2014-08-31

文章信息/Info

Title:
Association of GLP-1 and its receptor agonist with inflammation and oxidative stress
作者:
王兴纯; 曲伸
作者单位：200072　上海，同济大学附属上海市第十人民医院内分泌科（王兴纯,曲伸）；211100，南京医科大学（王兴纯） 　　
Author(s):
Wang Xingchun; Qu Shen.
Department of Endocrinology，Shanghai 10th People's Hospital，Tongji University，Shanghai 200072，China；Nanjing Medical University， Nanjing 211100， China Corresponding author：Qu Shen，Email：qushencn@hotmail.com
关键词:
GLP-1受体激动剂; 炎症; 氧化应激; 信号通路
Keywords:
GLP-1 receptor agonist; Inflammation; Oxidative stress; Signal pathway
DOI:
10.3760/cma.j.issn.1673-4157.2014.04.014
摘要:
胰高血糖素样肽（GLP）-1受体激动剂的作用包括增强葡萄糖依赖性的胰岛素分泌、抑制葡萄糖依赖性的胰高血糖素的分泌、延缓胃排空、降低食欲、减少食物摄入量及减轻体重。此类药物还可通过减少炎性因子的释放、减少巨噬细胞浸润以及改善炎性反应相关的信号通路等机制降低机体C反应蛋白水平，改善机体炎性反应状态。另外，此类药物还通过降低活性氧簇、一氧化氮合酶和内皮素改善机体氧化应激状态。
Abstract:
The roles of glucagon-like peptide-1（GLP-1） receptor agonist includes enhancing glucose dependent insulin secretion，inhibiting glucose dependent glucagon secretion，delaying gastric emptying，reducing appetite，food intake and body weight. These drugs can reduce the level of C reactive protein and improve inflammation by reducing the release of inflammatory factors，reducing macrophage infiltration and improving inflammation related signaling pathway. In addition，GLP-1 also improves oxidative stress by reducing reactive oxygen species，nitric oxide synthase and endothelin-1.

参考文献/References:

　[1]　Kodera R，Shikata K，Kataoka HU，et al.Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes[J].Diabetologia，2011，54（4）：965-978. 　
[2]　Arakawa M，Mita T，Azuma K，et al.Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist，exendin-4[J].Diabetes， 2010，59（4）：1030-1037. 　
[3]　Varanasi A，Patel P，Makdissi A，et al.Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors[J].Endocr Pract，2012，18（2）：140-145. 　
[4]　Chiquette E，Toth PP，Ramirez G，et al.Treatment with exe-natide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers[J].Vasc Health Risk Manag，2012,8:621-629. 　
[5]　Bunck MC，Diamant M，Eliasson B，et al.Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition[J].Diabetes Care，2010，33（8）：1734-1737. 　
[6]　Derosa G，Franzetti IG，Querci F，et al.Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes[J].Diabet Med，2012，29（12）：1515-1523. 　
[7]　Cai YL，Hu XR，Yi B，et al.Glucagon-like peptide-1 receptor agonist protects against hyperglycemia-induced cardiocytes injury by inhibiting high mobility group box 1 expression[J].Mol Biol Rep， 2012，39（12）：10705-10711. 　
[8]　Lee YS，Park MS，Choung JS，et al.Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes[J].Diabetologia，2012，55（9）：2456-2468. 　
[9]　Hirata Y，Kurobe H，Nishio C，et al.Exendin-4，a glucagon-like peptide-1 receptor agonist，attenuates neointimal hyperplasia after vascular injury[J].Eur J Pharmacol，2013，699（1-3）：106-111.
[10]　Parthsarathy V，H?觟lscher C.The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain[J].Eur J Pharmacol，2013，700（1-3）：42-50.
[11]　Daousi C，Pinkney JH，Cleator J，et al.Acute peripheral adminis-tration of synthetic human GLP-1（7-36 amide） decreases circu-lating IL-6 in obese patients with type 2 diabetes mellitus：A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?[J].Regul Pept，2013，183c：54-61.
[12]　Kim Chung LT，Hosaka T，Yoshida M，et al.Exendin-4，a GLP-1 receptor agonist，directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression[J].Biochem Biophys Res Commun，2009， 390（3）：613-618.
[13]　Chen H，Simar D，Pegg K，et al.Exendin-4 is effective against metabolic disorders induced by intrauterine and postnatal over-nutrition in rodents[J].Diabetologia，2014，57（3）：614-622.
[14]　Ojima A，Ishibashi Y，Matsui T，et al.Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine Genera-tion in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein argi-nine methyltranferase-1 expression[J].Am J Pathol，2013，182（1）：132-141.
[15]　Hattori Y，Jojima T，Tomizawa A，et al.A glucagon-like peptide-1 （GLP-1） analogue，liraglutide，upregulates nitric oxide produc-tion and exerts anti-inflammatory action in endothelial cells[J].Diabetologia，2010，53（10）：2256-2263.
[16]　Pugazhenthi U，Velmurugan K，Tran A，et al.Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodi-esterase inhibitors：potential therapeutic benefits in diabetic patients[J].Diabetologia，2010，53（11）：2357-2368.
[17]　Dalmas E，Clément K，Guerre-Millo M.Defining macrophage phenotype and function in adipose tissue[J].Trends Immunol，2011，32（7）：307-314.
[18]　Wang Y，Parlevliet ET，Geerling JJ，et al.Exendin-4 decreases liver inflammation and atherosclerosis development simultane-ously by reducing macrophage infiltration[J].Br J Pharmacol，2014，171（3）：723-734.
[19]　Burgmaier M，Liberman A，M?觟llmann J，et al.Glucagon-like peptide-1（GLP-1） and its split products GLP-1（9-37） and GLP-1（28-37） stabilize atherosclerotic lesions in apoe-/- mice[J].Atherosclerosis， 2013，231（2）：427-435.
[20]　Hogan AE，Gaoatswe G，Lynch L，et al.Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus[J].Diabetologia， 2014，57（4）：781-784.
[21]　Ishibashi Y，Matsui T，Takeuchi M，et al.Glucagon-like peptide-1 （GLP-1） inhibits advanced glycation end product （AGE）-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor（RAGE） expression[J].Biochem Biophys Res Commun，2010，391（3）：1405-1408.
[22]　高慧亭，徐丽姝，李东风，等.GLP-1对非酒精性脂肪肝大鼠肝氧化应激及TNF-?琢，TGF-β1的影响[J].南方医科大学学报，2013，33（11）：1661-1664.
[23]　Shiraki A，Oyama JI，Komoda H，et al.The glucagon-like peptide 1 analog liraglutide reduces TNF-?琢-induced oxidative stress and inflammation in endothelial cells[J].Atherosclerosis，2012，221（2）：375-382.
[24]　Dai Y，Mehta JL，Chen M.Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation[J].Cardiovasc Drugs Ther，2013，27（5）：371-380
[25]　Herrero L，Shapiro H，Nayer A，et al.Inflammation and adipose tissue macrophages in lipodystrophic mice[J].Proc Natl Acad Sci U S A，2010，107（1）：240-245.
[26]　Baker RG，Hayden MS，Ghosh S.NF-kappa B，Inflammation， and Metabolic Disease[J].Cell Metab，2011，13（1）：11-22.
[27]　Zhang L，Yang M，Ren H，et al.GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK[J].Liver Int，2013，33（5）：794-804.

相似文献/References:

[1]张红 章向成 朱大龙.炎性反应与糖尿病肾病[J].国际内分泌代谢杂志,2015,(01):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
　Zhang Hong*,Zhang Xiangcheng,Zhu Dalong..Role of inflammation in diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):49.[doi:10.3760/cma.j.issn.1673-4157.2015.01.012]
[2]刘琦,周赛君,孟振兴,等.P2X7受体与糖尿病视网膜病变[J].国际内分泌代谢杂志,2015,(02):127.[doi:10.3760/cma.j.issn.1673-4157.2015.02.015]
　Liu Qi,Zhou Saijun,Meng Zhenxing,et al.P2X7 receptor and diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2015,(04):127.[doi:10.3760/cma.j.issn.1673-4157.2015.02.015]
[3]邵滢,王秋月.MiRNA-150与糖尿病肾病[J].国际内分泌代谢杂志,2015,(03):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
　Shao Ying,Wang Qiuyue..MiRNA-150 and diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(04):173.[doi:10.3760/cma.j.issn.1673-4157.2015.03.008]
[4]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
　Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[5]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
　Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
[6]邵金双,邸阜生.网膜素抗炎作用及与代谢相关疾病的关系[J].国际内分泌代谢杂志,2014,(01):29.[doi:10.3760/cma.j.issn.1673-4157.2014.01.008]
　Shao Jinshuang*,Di Fusheng ..Anti-inflammatory effect of omentin and its relationship with metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(04):29.[doi:10.3760/cma.j.issn.1673-4157.2014.01.008]
[7]王兴纯,曲伸.胰高血糖素样肽-1受体激动剂与非酒精性脂肪性肝病[J].国际内分泌代谢杂志,2014,(01):40.[doi:10.3760/cma.j.issn.1673-4157.2014.01.011]
　Wang Xingchun*,Qu Shen.Glucagon like peptide-1 receptor agonist and nonalcoholic fatty liver disease[J].International Journal of Endocrinology and Metabolism,2014,(04):40.[doi:10.3760/cma.j.issn.1673-4157.2014.01.011]
[8]冯红,徐勇,苟芳,等.炎症小体与糖尿病并发症[J].国际内分泌代谢杂志,2014,(01):46.[doi:10.3760/cma.j.issn.1673-4157.2014.01.013]
　Feng Hong,Xu Yong,Gou Fang,et al.Inflammasome and diabetic complications[J].International Journal of Endocrinology and Metabolism,2014,(04):46.[doi:10.3760/cma.j.issn.1673-4157.2014.01.013]
[9]郑仁东 刘超.炎性反应与甲状腺肿瘤[J].国际内分泌代谢杂志,2015,(06):417.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.015]
　Zheng Rendong,Liu Chao.Inflammation and thyroid tumor[J].International Journal of Endocrinology and Metabolism,2015,(04):417.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.015]

备注/Memo

备注/Memo:
基金项目：2012年中华医学会临床医学科研专项基金（120120550355）；2012上海市卫生局申康慢病综合防治项目（SHDC12012303） 通信作者：曲伸，Email:qushencn@hotmail.com
更新日期/Last Update: 2014-07-20